Galapagos NV has identified a second preclinical compound in its alliance with Janssen Pharmaceutica NV, triggering a $5.3 million milestone payment to Galapagos.   The two companies entered the alliance in 2007, under which Janssen has option rights to acquire worldwide, commercial licenses to certain Galapagos internal programs.     “We are very pleased to announce the delivery of a second candidate drug in the alliance with Janssen,” said Onno van de Stolpe, chief executive office...